NLST 中筛查检出 I 期肺癌的生存分析
基于美国国家肺癌筛查试验(NLST),纳入低剂量 CT 组 324 例与胸部 X 线组 125 例筛查检出 I 期肺癌患者,采用竞争风险与 Cox 模型分析肺癌特异性生存。低剂量 CT 组 10 年生存率为 73.4%,优于胸部 X 线组的 64.6%,两组均高于 SEER 队列的 55.6%;肿瘤较小和手术治疗与更好生存相关。
要点
- 低剂量 CT 筛查检出 I 期肺癌的 10 年生存率高于胸部 X 线筛查
- 原发肿瘤小于中位数 17 mm 者生存可能性更高
- 非手术治疗相比全切除与生存可能性降低相关
核心结论
- 筛查检出 I 期肺癌的长期肺癌特异性生存,低剂量 CT 组优于胸部 X 线组,也优于一般人群队列。
研究设计与样本
- 研究队列为 NLST 中全部筛查检出的 I 期肺癌参与者,低剂量 CT 组 324 例,胸部 X 线组 125 例。
- 采用累积发生率竞争风险方法分析,并用 Cox 比例风险模型评估生存相关因素。
- 与来自美国国家癌症研究所 SEER 项目的类似队列进行比较。
主要发现
- 低剂量 CT 组 10 年生存率为 73.4%,高于胸部 X 线组的 64.6%(P = .05)。
- SEER 队列 10 年生存率为 55.6%,低于低剂量 CT 组(P < .001)和胸部 X 线组(P = .04)。
- 低剂量 CT 组生存可能性更高(HR,0.69;95% CI,0.5-0.98)。
- 原发肿瘤小于中位数 17 mm 者生存可能性更高(HR,0.61;95% CI,0.42-0.88)。
- 局限切除与全切除之间无生存差异(HR,1.11;95% CI,0.6-1.9);非手术治疗相比全切除与生存可能性降低相关(HR,3.1;95% CI,1.6-6.0)。
关键数值与推荐
- 低剂量 CT 组 10 年生存率为 73.4%,胸部 X 线组为 64.6%,SEER 队列为 55.6%。
- 原发肿瘤大小中位数为 17 mm。
临床怎么用
- 对筛查检出的 I 期肺癌,可参考低剂量 CT 筛查背景下的长期生存数据与手术治疗获益信息进行病情沟通。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is limited information about survival of stage I lung cancer diagnosed by screening. RESEARCH QUESTION: What was the survival rate of screen-detected stage I lung cancer in the National Lung Screening Trial (NLST), and was it affected by screening method, patient or tumor characteristics, or treatment method? STUDY DESIGN AND METHODS: The study cohort consisted of all NLST participants with screen-detected stage I lung cancer. Lung cancer-specific survival for stage I overall and for IA and IB substages were compared in the low-dose CT and chest radiography (CXR) screening randomization arms and with an analogous cohort from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute; the cumulative incidence competing risk method was used for analysis. Cox proportional hazards models were used to evaluate the association between lung cancer-specific survival and screening arm, patient factors, primary tumor size, and treatment. RESULTS: There were 324 screen-detected stage I lung cancers in the low-dose CT arm and 125 in the CXR arm. The 10-year survival in the low-dose CT arm was greater than in the CXR arm (73.4% vs 64.6%; P = .05), and both were greater than in the Surveillance, Epidemiology, and End Results cohort (55.6%; P < .001 vs low-dose CT arm, P = .04 vs CXR arm). Proportional hazards models revealed a greater likelihood of survival in the low-dose CT arm (hazard ratio [HR], 0.69; 95% CI, 0.5-0.98) and with primary tumor size below the median of 17 mm (HR, 0.61; 95% CI, 0.42-0.88). There was no survival difference between treatment with limited resection vs full resection (HR, 1.11; 95% CI, 0.6-1.9), whereas nonsurgical treatment was associated with a reduced likelihood of survival compared with full resection (HR, 3.1; 95% CI, 1.6-6.0). INTERPRETATION: Long-term lung cancer-specific survival of stage I lung cancer was greater with low-dose CT imaging than with CXR screening or in the general population, for smaller primary tumor size, and with surgical treatment.
引用
- Gierada DS, Pinsky PF. Survival Following Detection of Stage I Lung Cancer by Screening in the National Lung Screening Trial. Chest. 2020. PMID: 32822676. doi:10.1016/j.chest.2020.08.2048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。